MEA Antibodies Market

MEA Antibodies Market Size (2023 to 2028)

The size of the Middle East & Africa Antibodies Market was valued at 7.46 billion in 2023 and estimated to reach USD 9.68 billion by the end of 2028, with a growing potential of 5.36 % during the forecast period.

Antibodies (Ab’s) are proteins produced by Plasma cells (differentiated B-Cells) that helps the immune system to detect and neutralize pathogens such as Viruses and bacteria. Antibodies can be triggered and directed at microorganisms, foreign proteins, and toxins. These antibodies are used as diagnostics as well as Therapeutic purposes for several indications of diseases, including but not limited to rheumatoid arthritis, Crohn’s disease, macular degeneration, asthma, and hypercholesterolemia.

Some of the major factors that are influencing the Middle East and Africa Antibodies market are the rising rate of adoption to therapeutic antibodies in the cost-sensitive market, innovative products, growing chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies. On the other hand, side effects associated with antibody treatment and increasing cost of treatment are the factors that hamper the market's growth.

This research report on the MEA antibodies market has been segmented and sub-segmented into the following categories:

By Product Type:

• Monoclonal Antibodies
  • Murine
  • Chimeric
  • Humanized
  • Human
• Polyclonal Antibodies
  • Type I
  • Type II
  • Type III
  • Type IV
  • Type V
  • Type VI
  • Type VII
  • Type VIII
• Anti-body drug complexes
  • Immunogen Technology
  • Seattle Genetics Technology
  • Immunomedics Technology

By Indication:

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Other)

By End User:

• Hospitals/Clinics
• Research institute
• Diagnostics laboratories

By Application:

• Medical
• Experimental
• Western blot
• ELISA
• Radioimmune Assays
• Immunofluorescence
• Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The MEA antibodies market is expected to register a moderate share in the global market during the forecast period due to the improving healthcare sector, supportive government incentives and investment for research & development activities, and advancing infrastructure. Increasing R&D Activities are uplifting the market growth, as the monoclonal antibody is used as a study or diagnostic tool by the researchers, who use various methodological techniques to improve antibody production. These antibodies can be used to evaluate immunoassays and create medical treatments. Immunoassay tests are used to see if a patient's blood or other fluid sample has a certain antigen or antibody. It's commonly used in the creation of new drugs, drug monitoring, and food sample testing.

In the Middle East and Africa, Saudi Arabia dominates the Antibodies market owing to the rising prevalence of cardiovascular illness, increase in the elderly population, and increased demand for antibodies for research reproductivity. In addition, surging government expenditures in reducing healthcare costs and enhanced development efforts to provide better diagnostic treatment are boosting the market.

The market in the United Arab Emirates is estimated to grow significantly in the coming years. The market growth is expected to be driven by ongoing technological advancements, improved accessibility, and rising disposable income will influence the industry's development in this region and the various strategic initiatives these industries undertake.

KEY MARKET PLAYERS:

Companies that play a prominent role in the MEA antibodies market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc, ThermoFisher Scientific Inc, Eli Lilly, and company A.G. Scientific Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.